AllianceBernstein’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,424
Closed -$139K 3374
2022
Q1
$139K Buy
1,424
+5
+0.4% +$642 ﹤0.01% 3070
2021
Q4
$232K Sell
1,419
-113
-7% -$24.8K ﹤0.01% 3021
2021
Q3
$418K Sell
1,532
-70
-4% -$21.4K ﹤0.01% 2825
2021
Q2
$634K Buy
1,602
+150
+10% +$70K ﹤0.01% 2715
2021
Q1
$784K Buy
1,452
+272
+23% +$169K ﹤0.01% 2499
2020
Q4
$446K Sell
1,180
-204
-15% -$81.1K ﹤0.01% 2644
2020
Q3
$523K Sell
1,384
-84
-6% -$37.1K ﹤0.01% 2504
2020
Q2
$722K Buy
1,468
+58
+4% +$25.9K ﹤0.01% 2382
2020
Q1
$518K Sell
1,410
-68
-5% -$35.2K ﹤0.01% 2338
2019
Q4
$1.05M Sell
1,478
-78
-5% -$53.7K ﹤0.01% 2261
2019
Q3
$999K Hold
1,556
﹤0.01% 2247
2019
Q2
$1.36M Sell
1,556
-27
-2% -$18.6K ﹤0.01% 2177
2019
Q1
$914K Sell
1,583
-263
-14% -$110K ﹤0.01% 2281
2018
Q4
$518K Sell
1,846
-6
-0.3% -$2.37K ﹤0.01% 2464
2018
Q3
$889K Buy
1,852
+291
+19% +$125K ﹤0.01% 2385
2018
Q2
$707K Buy
1,561
+264
+20% +$167K ﹤0.01% 2471
2018
Q1
$763K Hold
1,297
﹤0.01% 2374
2017
Q4
$805K Hold
1,297
﹤0.01% 2384
2017
Q3
$1.19M Hold
1,297
﹤0.01% 2182
2017
Q2
$1.21M Hold
1,297
﹤0.01% 2202
2017
Q1
$1.23M Hold
1,297
﹤0.01% 2134
2016
Q4
$1.04M Hold
1,297
﹤0.01% 2244
2016
Q3
$1.09M Hold
1,297
﹤0.01% 2178
2016
Q2
$1.07M Hold
1,297
﹤0.01% 2178
2016
Q1
$1.44M Buy
1,297
+17
+1% +$17.4K ﹤0.01% 1867
2015
Q4
$1.6M Sell
1,280
-20
-2% -$33.1K ﹤0.01% 1805
2015
Q3
$1.76M Sell
1,300
-1
-0.1% -$1.65K ﹤0.01% 1752
2015
Q2
$2.34M Buy
1,301
+487
+60% +$756K ﹤0.01% 1658
2015
Q1
$1.31M Buy
814
+167
+26% +$248K ﹤0.01% 2031
2014
Q4
$492K Hold
647
﹤0.01% 2518
2014
Q3
$256K Hold
647
﹤0.01% 2697
2014
Q2
$391K Buy
647
+60
+10% +$33.4K ﹤0.01% 2589
2014
Q1
$403K Sell
587
-96
-14% -$64.3K ﹤0.01% 2516
2013
Q4
$445K Hold
683
﹤0.01% 2486
2013
Q3
$405K Sell
683
-89
-12% -$40.1K ﹤0.01% 2574
2013
Q2
$243K Buy
+772
New +$214K ﹤0.01% 2789

Other funds holding TCRT

AllianceBernstein's TCRT Position: Q2 2022 in Review

AllianceBernstein sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 1,424 shares — an estimated $139K sold.

AllianceBernstein first reported a position in TCRT in Q2 2013 and held it in 36 quarters. The position peaked at $2.34M in Q2 2015. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • AllianceBernstein reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 1,424 Alaunos Therapeutics shares in Q2 2022, an estimated $139K.
  • AllianceBernstein first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 36 quarters.
  • AllianceBernstein's Alaunos Therapeutics position peaked at $2.34M in Q2 2015.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.